Syndecan-4 is an emerging target for cancer treatment, and several cancer therapeutics have been found to downregulate it like trastuzumab (humanized anti-HER2 monoclonal antibody) and panitumumab (human anti-EGFR monoclonal antibody) (50). Here, EGFR is linked to cancer.